ASX
LCT 0.060    Last updated 1.21 am
Fact sheet
The following fact sheets provide a summary of our current business and research pipeline.
Register for email updates
Register now to receive our newsletter and updates on LCT’s activities and progress.

Fact sheet

The following fact sheets provide a summary of our current business and research pipeline.

Cell therapy for neurodegenerative diseases

Living Cell Technologies Limited (LCT) is an Australasian biotechnology company improving the wellbeing of people with serious diseases worldwide by discovering, developing and commercialising breakthrough treatments that use the regenerative properties of naturally occurring cells.

 

LCT’s lead product NTCELL® is an alginate coated capsule containing clusters of neonatal porcine choroid plexus cells. After transplantation NTCELL functions as a biological factory producing nerve growth factors to promote new central nervous system growth and repair disease induced nerve degeneration.

 

NTCELL is in Phase I/IIa clinical trial in New Zealand for the treatment of Parkinson’s disease. It has the potential to be used in a number of other central nervous system indications such as Huntington’s, Alzheimer’s and motor neurone diseases.

 

LCT’s proprietary encapsulation technology, IMMUPEL™, allows cell therapies to be used without the need for co-treatment with drugs that suppress the immune system.

 

LCT holds a 50% interest in Diatranz Otsuka Limited which is developing a cell therapy for type 1 diabetes.

 

LCT is listed on the Australian (ASX: LCT) and US (OTCQX: LVCLY) stock exchanges. The company is incorporated in Australia, with its operations based in New Zealand.

— 28 January 2015

Appendix 4C Quarterly Report

Living Cell Technologies Limited today announced its quarterly cash flow report for the quarter ended 31 December 2014. The company ended the quarter with a cash balance of $6,972,225 compared to $3,172,520 last quarter, primarily due to financing cash inflows of $3m from a private placement of shares and $1m from the share placement plan.

Read More Read Less

— 15 December 2014

LCT completes patient implants in Parkinson's trial

The final patient has been successfully implanted in LCT's Phase I/IIa clinical trial of regenerative cell therapy NTCELL® for Parkinson’s disease. The operation took place at Auckland City Hospital last week.

Read More Read Less
Load More

— 8 May 2014

Please refer to our news releases

Load More

There are no forthcoming events at present.

Load More
Announcements

— 28 January 2015

Appendix 4C Quarterly Report

Living Cell Technologies Limited today announced its quarterly cash flow report for the quarter ended 31 December 2014. The company ended the quarter with a cash balance of $6,972,225 compared to $3,172,520 last quarter, primarily due to financing cash inflows of $3m from a private placement of shares and $1m from the share placement plan.

Read More Read Less

— 15 December 2014

LCT completes patient implants in Parkinson's trial

The final patient has been successfully implanted in LCT's Phase I/IIa clinical trial of regenerative cell therapy NTCELL® for Parkinson’s disease. The operation took place at Auckland City Hospital last week.

Read More Read Less
Load More
LCT in the News

— 8 May 2014

Please refer to our news releases

Load More
Events

There are no forthcoming events at present.

Load More
© 2015 Living Cell Technologies Limited.
site by { brownpaperbag }